Home › Companies › NewAmsterdam Pharma Company N.V. › 2024-2025
Compiled from SEC Form N-PX filings and NewAmsterdam Pharma Company N.V.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 4, 2025: 11 items on NewAmsterdam Pharma Company N.V.’s Form 8-K, filed June 6, 2025: 6 approved · 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore NewAmsterdam Pharma Company N.V. in the interactive database Compare manager voting policies
These tallies are NewAmsterdam Pharma Company N.V.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2024 | 83,508,600 | 5,608 | 80,676 | -- | -- | 99.9% | Approved | — |
| 2. The discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024 | 79,671,210 | 29,664 | 49,158 | -- | 3,844,852 | 99.9% | Approved | — |
| 3. The appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the Company's annual accounts for the fiscal year 2025 | 83,569,325 | 5,798 | 19,761 | -- | -- | 99.9% | Approved | — |
| 4. The selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the Company's audit committee | 83,557,642 | 17,636 | 19,606 | -- | -- | 99.9% | Approved | — |
| Elect Director: Wouter Joustra | 79,415,918 | 313,937 | 20,177 | -- | 3,844,852 | 99.6% | Not verified | — |
| Elect Director: Mark C. McKenna | 79,264,690 | 465,766 | 19,576 | -- | 3,844,852 | 99.4% | Not verified | — |
| Elect Director: Adele Gulfo | 79,603,736 | 126,719 | 19,577 | -- | 3,844,852 | 99.8% | Not verified | — |
| Elect Director: Michael Davidson, M.D. | 70,484,270 | 9,247,819 | 17,943 | -- | 3,844,852 | 88% | Not verified | — |
| Elect Director: James N. Topper | 70,539,295 | 9,190,894 | 19,843 | -- | 3,844,852 | 88% | Not verified | — |
| 7. The extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital | 71,365,533 | 12,226,858 | 2,493 | -- | -- | 85% | Approved | — |
| 8. The 2024 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote | 78,601,396 | 1,126,551 | 22,085 | -- | 3,844,852 | 99% | Approved | — |
Source: NewAmsterdam Pharma Company N.V., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.
Each item below shows how the 119 asset managers that disclosed a NewAmsterdam Pharma Company N.V. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NewAmsterdam Pharma Company N.V.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Adele Gulfo
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Adele Gulfo”): 79,603,736 for, 126,719 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 12,197,597 for, 115,421 against, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 0 | 115,421 | 0 | 0 | Against |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Mark McKenna
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Mark C. McKenna”): 79,264,690 for, 465,766 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 12,197,597 for, 115,421 against, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 0 | 115,421 | 0 | 0 | Against |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Wouter Joustra
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Wouter Joustra”): 79,415,918 for, 313,937 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 12,313,018 for, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
91% of fund votes cast · no official result
Description as filed by funds: Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: James N. Topper
The 29 asset managers below reported 10,892,313 for, 1,089,254 against, 16,048 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 636,388 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 0 | 132,271 | 0 | 0 | Against |
| Eaton Vance | 0 | 115,421 | 0 | 0 | Against |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 92,300 | 0 | 0 | Against |
| American Century | 0 | 53,654 | 0 | 0 | Against |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 19,093 | 0 | 0 | Against |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 0 | 11,164 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 7,729 | 0 | 0 | Against |
| ALGER PORTFOLIOS | 0 | 6,809 | 0 | 0 | Against |
| Forethought Variable Insurance Trust | 6,700 | 0 | 0 | 0 | For |
| State Street | 6,574 | 0 | 0 | 0 | For |
Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.
91% of fund votes cast · no official result
Description as filed by funds: Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: Michael Davidson
The 29 asset managers below reported 10,892,313 for, 1,089,254 against, 16,048 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 636,388 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 0 | 132,271 | 0 | 0 | Against |
| Eaton Vance | 0 | 115,421 | 0 | 0 | Against |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 92,300 | 0 | 0 | Against |
| American Century | 0 | 53,654 | 0 | 0 | Against |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 19,093 | 0 | 0 | Against |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 0 | 11,164 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 7,729 | 0 | 0 | Against |
| ALGER PORTFOLIOS | 0 | 6,809 | 0 | 0 | Against |
| Forethought Variable Insurance Trust | 6,700 | 0 | 0 | 0 | For |
| State Street | 6,574 | 0 | 0 | 0 | For |
Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: REAPPOINTMENT OF JAMES N. TOPPER AS NON-EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEETING.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: James N. Topper”): 70,539,295 for, 9,190,894 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 4,484 | 0 | 0 | Against |
| EA Series Trust | 2,123 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 314 | 0 | 0 | 0 | For |
| GuideStone | 0 | 10 | 0 | 0 | Against |
Fund voting reports, all 8 managers: 318,463 for, 4,494 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RWC Asset Management LLP | 8,494 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 8,494 for.
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: REAPPOINTMENT OF MICHAEL DAVIDSON M.D. AS EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEETING.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Michael Davidson, M.D.”): 70,484,270 for, 9,247,819 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 4,484 | 0 | 0 | Against |
| EA Series Trust | 2,123 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 314 | 0 | 0 | Against |
| GuideStone | 0 | 10 | 0 | 0 | Against |
Fund voting reports, all 8 managers: 318,149 for, 4,808 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RWC Asset Management LLP | 8,494 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 8,494 for.
85% Approved · of votes cast
Description as filed by funds: EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ACQUIRE ORDINARY SHARES AND DEPOSITORY RECEIPTS FOR ORDINARY SHARES IN THE COMPANY'S CAPITAL.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“7. The extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital”): 71,365,533 for, 12,226,858 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital.”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of NewAmsterdam Pharma Company N.V.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorize Repurchase of Up to 10 Percent of Issued Share Capital” (2 managers, 8,504 against).
The 35 asset managers below reported 10,381,594 for, 1,938,968 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 756,613 | 0 | 0 | Against |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 473,047 | 0 | 0 | Against |
| Fidelity | 262,423 | 16,926 | 0 | 0 | Mixed |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 0 | 175,949 | 0 | 0 | Against |
| Principal | 0 | 153,014 | 0 | 0 | Against |
| First Trust | 0 | 132,271 | 0 | 0 | Against |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 92,300 | 0 | 0 | Against |
| American Century | 0 | 53,654 | 0 | 0 | Against |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 0 | 21,490 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 19,093 | 0 | 0 | Against |
| Brighthouse | 16,106 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 11,164 | 0 | 0 | Against |
Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING THE FISCAL YEAR ENDED DECEMBER 31, 2024.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“2. The discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024”): 79,671,210 for, 29,664 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 12,313,018 for, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“1. The adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2024”): 83,508,600 for, 5,608 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Company's shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2024”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of NewAmsterdam Pharma Company N.V.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Adopt Financial Statements and Statutory Reports” (2 managers, 8,504 for).
The 35 asset managers below reported 12,304,514 for, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.
Combines 6 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: Non-binding, advisory vote to approve the 2024 compensation of named executive officers.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“8. The 2024 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote”): 78,601,396 for, 1,126,551 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the 2024 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Fund voting reports, all 36 managers: 12,304,524 for, 16,048 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 16,116,418 | 0 | 0 | 0 | For |
| FCPM III SERVICES B.V. | 10,632,113 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 8,625,498 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,978,534 | 0 | 0 | 0 | For |
| Capital Group | 6,650,136 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 5,237,567 | 0 | 0 | 0 | For |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | 0 | 0 | 0 | For |
| Wellington | 2,859,797 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 2,777,850 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,504,884 | 0 | 0 | 0 | For |
| Janus Henderson | 2,032,700 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,943,189 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,678,915 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,504,856 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,374,177 | 0 | 0 | 0 | For |
| MAVERICK CAPITAL LTD | 873,630 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 705,650 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 519,149 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 398,223 | 0 | 0 | 0 | For |
| JPMorgan | 362,868 | 0 | 0 | 0 | For |
| Slate Path Capital LP | 319,000 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 303,520 | 0 | 0 | Against |
| Duquesne Family Office LLC | 287,535 | 0 | 0 | 0 | For |
No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| NEW ECONOMY FUND | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| First Trust | 0 | 0 | 0 | 0 | -- |
| Eaton Vance | 0 | 0 | 0 | 0 | -- |
| Columbia Threadneedle | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| AMG FUNDS | 0 | 0 | 0 | 0 | -- |
| MERIDIAN FUND INC | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
| TIFF INVESTMENT PROGRAM | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 0 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 35 managers: 16,048 abstained, 12,304,514 1 year. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0 | 0 | 0 | 0 | -- |
| FCPM III SERVICES B.V. | 10,632,113 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 0 | 0 | 0 | 0 | -- |
| VIKING GLOBAL INVESTORS LP | 0 | 0 | 0 | 0 | -- |
| Capital Group | 0 | 0 | 0 | 0 | -- |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0 | 0 | 0 | 0 | -- |
| Medicxi Ventures Management (Jersey) Ltd | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| JENNISON ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| Janus Henderson | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| PICTET ASSET MANAGEMENT SA | 0 | 0 | 0 | 0 | -- |
| Cormorant Asset Management, LP | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| MAVERICK CAPITAL LTD | 0 | 0 | 0 | 0 | -- |
| TimesSquare Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Slate Path Capital LP | 0 | 0 | 0 | 0 | -- |
| BNP Paribas Asset Management Holding S.A. | 0 | 0 | 0 | 0 | -- |
| Duquesne Family Office LLC | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| READYSTATE ASSET MANAGEMENT LP | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 85 managers: 10,729,005 for, 225 not voted, 66,450,363 1 year. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025 BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“4. The selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the Company's audit committee”): 83,557,642 for, 17,636 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders ratified the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the Company's audit committee.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 12,313,018 for, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY ANNUAL ACCOUNTS AND DUTCH STATUTORY BOARD REPORT FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“3. The appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the Company's annual accounts for the fiscal year 2025”): 83,569,325 for, 5,798 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the Company's annual accounts for the fiscal year 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 35 asset managers below reported 12,304,514 for, 16,048 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 4,485,123 | 0 | 0 | 0 | For |
| Vanguard | 1,895,306 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,674,220 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 787,905 | 0 | 0 | 0 | For |
| AllianceBernstein | 756,613 | 0 | 0 | 0 | For |
| Aberdeen | 636,388 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 473,047 | 0 | 0 | 0 | For |
| Fidelity | 279,349 | 0 | 0 | 0 | For |
| JPMorgan | 218,956 | 0 | 0 | 0 | For |
| Equitable | 175,949 | 0 | 0 | 0 | For |
| Principal | 153,014 | 0 | 0 | 0 | For |
| First Trust | 132,271 | 0 | 0 | 0 | For |
| Eaton Vance | 115,421 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 107,461 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 92,300 | 0 | 0 | 0 | For |
| American Century | 53,654 | 0 | 0 | 0 | For |
| AMG FUNDS | 47,000 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 31,640 | 0 | 0 | 0 | For |
| Global X | 29,779 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 28,625 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 28,580 | 0 | 0 | 0 | For |
| BlackRock | 21,490 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 19,093 | 0 | 0 | 0 | For |
| Brighthouse | 58 | 0 | 16,048 | 0 | Abstain |
| ALGER FUNDS | 11,164 | 0 | 0 | 0 | For |
Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 112,169,291 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 4.00% |
| 2 | Vanguard | 1.69% |
| 3 | Prudential/PGIM | 1.49% |
| 4 | NEW ECONOMY FUND | 0.70% |
| 5 | AllianceBernstein | 0.67% |
| 6 | Aberdeen | 0.57% |
| 7 | AB DISCOVERY GROWTH FUND, INC. | 0.42% |
| 8 | Fidelity | 0.25% |
| 9 | JPMorgan | 0.20% |
| 10 | Equitable | 0.16% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 14.37% |
| 2 | FCPM III SERVICES B.V. | 9.48% |
| 3 | Bain Capital Life Sciences Investors, LLC | 9.34% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 7.69% |
| 5 | VIKING GLOBAL INVESTORS LP | 6.22% |
| 6 | Capital Group | 5.93% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4.67% |
| 8 | Medicxi Ventures Management (Jersey) Ltd | 2.56% |
| 9 | Wellington | 2.55% |
| 10 | JENNISON ASSOCIATES LLC | 2.48% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| James N. Topper, M.D., Ph.D. | 14.64% | DEF14A |
| Capital World Investors | 10.87% | 13G |
| ForGrowth NAP B.V. | 8.31% | 13D |
| Frazier Life Sciences Public Fund, L.P. | 7.69% | 13D |
| Frazier Life Sciences X, L.P. | 6.53% | 13D |
| Michael Davidson, M.D. | 3.98% | DEF14A |
| VIKING GLOBAL INVESTORS LP | 3.75% | 13G |
| Wellington Management | 3.16% | 13F |
| John Kastelein, M.D., Ph.D. FESC | 1.88% | DEF14A |
| BCLS Fund III Investments, LP | 1.84% | 13D |
Percentages above are of 112,169,291 shares outstanding, as reported by NewAmsterdam Pharma Company N.V. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NewAmsterdam Pharma Company N.V.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At NewAmsterdam Pharma Company N.V.'s shareholder meeting held June 4, 2025, in the 2024-2025 proxy season, 119 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,109 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding, advisory vote to approve the 2024 compensation of named executive officers. — NewAmsterdam Pharma Company N.V.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NewAmsterdam Pharma Company N.V.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.
NewAmsterdam Pharma Company N.V. proxy season coverage: 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.